Last reviewed · How we verify
Pneumovax™23
Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria.
Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine, Prophylaxis in adults aged 50 years and older, Prophylaxis in high-risk populations including those with chronic diseases, immunocompromised states, or asplenia.
At a glance
| Generic name | Pneumovax™23 |
|---|---|
| Also known as | PPSV23, Pneumococcal polysaccharide vaccine, PPV23 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Polysaccharide vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharide antigens from 23 different strains of pneumococcus. When administered, these antigens trigger B-cell and T-cell mediated immune responses, leading to the production of specific antibodies and memory cells that provide protection against pneumococcal infection. This helps prevent invasive pneumococcal diseases including pneumonia, bacteremia, and meningitis in vaccinated individuals.
Approved indications
- Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine
- Prophylaxis in adults aged 50 years and older
- Prophylaxis in high-risk populations including those with chronic diseases, immunocompromised states, or asplenia
Common side effects
- Injection site reactions (erythema, induration, soreness)
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) (PHASE3)
- Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumovax™23 CI brief — competitive landscape report
- Pneumovax™23 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI